Table 3.

Factors significantly associated with severe disease course (univariate analysis).

	Total	Events	Cumulative incidence (95% C.I.)	Hazard Ratio (95% C.I.)	P value
Diagnosis
Malignant disease	52	3	6.12 (1.56–15.32)	1.00
Non-malignant disease	33	8	26.98 (12.36–44.00)	4.70 (1.25–17.76)	0.02
Lansky (10-point effect)	84	11	-	0.96 (0.92–0.99)	0.01
Chronic GVHD (number of allo-HCT patients with a follow-up > 100 days)	n = 75	n = 8
Yes	12	5	44.44 (13.97–71.59)	9.95 (2.37–41.73)	0.002
No	63	3	4.93 (1.28–12.49)	1.00
Immunosuppressant drug(s)
Yes	53	11	22.03 (11.58–34.60)		0.01
No	32	0	0.00
Corticosteroids
Yes	24	6	25.00 (9.90–43.57)	3.20 (0.98–10.51)	0.06
No	61	5	9.49 (3.39–19.42)	1.00
Janus kinase inhibitor
Yes	13	4	89.17 (78.44–94.73)	3.42 (1.00–11.73)	0.05
No	72	7	69.23 (37.34–87.18)	1.00
Mycophenolic acid
Yes	9	5	44.44 (13.59–71.93)	9.80 (2.94–32.62)	0.0002
No	76	6	91.07 (81.04–95.93)	1.00
Symptomatic
Yes	52	10	20.44 (10.39–32.86)	7.42 (0.95–58.15)	0.06
No	33	1	3.70 (0.26–16.23)	1.00
Fever
Yes	37	9	25.08 (12.28–40.16)	6.80 (1.46–31.61)	0.01
No	47	2	5.29 (0.92–15.81)	1.00
Cough
Yes	26	8	32.69 (15.07–51.66)	6.93 (1.83–26.20)	0.004
No	59	3	5.83 (1.46–14.81)	1.00
Coinfection
Yes	23	7	31.82 (13.61–51.81)	5.15 (1.50–17.62)	0.009
No	61	4	7.46 (2.31–16.72)	1.00
C-reactive protein levels, mg/L (10-point effect)	63	10	-	1.10 (1.01–1.20)	0.04
Pulmonary radiological findings
Yes	18	8	45.00 (20.91–66.54)	7.21 (1.91–27.28)	0.004
No	42	3	8.35 (2.01–20.62)	1.00
Immunodeficiency scoring index
Low	18	0	100.00		0.002
Intermediate	13	6	53.85 (24.77–75.99)	-

Bold entries indicate significant p values.